Justine0325 (Talk | contribs) |
|||
(482 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
+ | <html> | ||
+ | <meta http-equiv="X-UA-Compatible" content="IE=edge"> | ||
+ | <style> | ||
+ | #sideMenu | ||
+ | { | ||
+ | display:none; /* Disable the display of the annoying side main menu*/ | ||
+ | } | ||
+ | |||
+ | #top_title | ||
+ | { | ||
+ | display:none; /* Disable the annoying title*/ | ||
+ | } | ||
+ | |||
+ | #content { padding:0px; width:100%; margin-left:0%; margin-right:0%;} | ||
+ | </style> | ||
+ | |||
<html> | <html> | ||
<head> | <head> | ||
<style> | <style> | ||
− | + | body { | |
− | + | background-color:white; | |
} | } | ||
− | + | .top { | |
− | + | position: absolute; | |
− | + | top: -1%; | |
− | + | left: 0%; | |
− | + | width: 100%; | |
− | + | box-sizing:border-box; | |
− | + | height: 115px; | |
− | + | font-family: Corbel; | |
− | + | overflow: visible; | |
− | + | z-index: +1; | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
} | } | ||
− | + | .mid { | |
− | + | position: absolute; | |
− | + | left: 5%; | |
− | + | width: 80%; | |
− | + | height: 100%; | |
+ | font-family: Corbel; | ||
} | } | ||
− | + | .mid2 { | |
− | + | position: absolute; | |
− | + | left: 0%; | |
− | + | width: 100%; | |
− | + | height: 100%; | |
− | + | font-family: Corbel; | |
− | + | } | |
− | + | .headline { | |
− | + | color: #ffe; | |
− | + | text-align: center; | |
− | + | padding-top: 40px; | |
− | + | padding-bottom: 60px; | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
} | } | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
+ | .header-subnav { | ||
+ | float: none; | ||
+ | background: #0D014D; | ||
+ | position: absolute; | ||
+ | text-align: center; | ||
+ | margin: 0 0; | ||
+ | top: 100%; | ||
+ | width: 100%; | ||
+ | box-sizing: border-box; | ||
+ | font-family: Corbel; | ||
+ | } | ||
+ | .header-subnav li { | ||
+ | float: none; | ||
+ | display: inline-block; | ||
+ | } | ||
+ | .header-subnav li a { | ||
+ | padding: 13px 1rem; | ||
+ | font-size: 13px; | ||
+ | text-decoration: none; | ||
+ | color: #ffe; | ||
+ | text-transform: uppercase; | ||
+ | display: block; | ||
+ | font-weight: bold; | ||
+ | letter-spacing: 1px; | ||
+ | transition: all 0.35s ease-in-out; | ||
+ | } | ||
+ | .header-subnav li a.is-active { | ||
+ | background: rgba(250, 250, 250, 0.15); | ||
+ | } | ||
+ | .header-subnav li a:hover { | ||
+ | border-radius: 6px; | ||
+ | background: #0080ff; | ||
+ | transition: all 0.35s ease-in-out; | ||
+ | } | ||
+ | .fixed1 { | ||
+ | position:fixed; | ||
+ | top: 13px; | ||
+ | } | ||
+ | .page { | ||
+ | } | ||
+ | .end { | ||
+ | background-color:#0D014D; | ||
+ | position: absolute; | ||
+ | left: 0px; | ||
+ | width: 100%; | ||
+ | height: 30%; | ||
+ | font-family: Corbel; | ||
+ | } | ||
+ | hr { | ||
+ | border: 0; | ||
+ | width: 80%; | ||
+ | color: #140731; | ||
+ | background-color: #140731; | ||
+ | height: 2px; | ||
+ | } | ||
+ | .end2 { | ||
+ | background-color:#0D014D; | ||
+ | position: absolute; | ||
+ | width: 100%; | ||
+ | height: 35%; | ||
+ | font-family: Corbel; | ||
+ | } | ||
+ | .sitemap { | ||
+ | background-color:#0D014D; | ||
+ | position: absolute; | ||
+ | width: 20%; | ||
+ | height: 35%; | ||
+ | font-family: Corbel; | ||
+ | } | ||
+ | .list li { | ||
+ | list-style:none; | ||
+ | background-image:url(https://static.igem.org/mediawiki/2016/5/58/CGU_Taiwan--sitemap.jpg); | ||
+ | background-repeat:no-repeat; | ||
+ | background-position:10px; | ||
+ | background-size:9%; | ||
+ | margin-bottom:-20%; | ||
+ | } | ||
+ | .list2 li { | ||
+ | list-style:none; | ||
+ | background-image:url(https://static.igem.org/mediawiki/2016/2/2f/CGU_Taiwan--sitemap2.jpg); | ||
+ | background-repeat:no-repeat; | ||
+ | background-position:6px; | ||
+ | background-size:7%; | ||
+ | margin-bottom:-10%; | ||
+ | } | ||
+ | .list3 li { | ||
+ | list-style:none; | ||
+ | background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg); | ||
+ | background-repeat:no-repeat; | ||
+ | background-position:5%; | ||
+ | background-size:2%; | ||
+ | margin-bottom:-10%; | ||
+ | } | ||
</style> | </style> | ||
</head> | </head> | ||
− | + | ||
− | < | + | <script> |
− | + | /* Dynamic top menu positioning | |
− | + | * | |
− | + | */ | |
− | + | var num = 110; //number of pixels before modifying styles | |
− | + | $(window).bind('scroll', function () { | |
− | + | if ($(window).scrollTop() > num) { | |
− | + | $('.header-subnav').addClass('fixed1'); | |
− | + | } else { | |
− | + | $('.header-subnav').removeClass('fixed1'); | |
− | + | } | |
− | + | }); | |
− | + | ||
− | + | ||
− | + | //USE SCROLL WHEEL FOR THIS FIDDLE DEMO | |
− | + | </script> | |
− | + | ||
− | + | <body> | |
− | + | <a name='anchor1'></a> | |
− | + | <div class="top"> | |
− | + | <img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg"> | |
− | + | </div> | |
− | + | ||
− | + | <header class="top"> | |
− | + | <div class="header-subnav"> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan">HOME</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements">ACHIEVEMENTS</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description">PROJECT</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software">MODELING</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices">HUMAN PRACTICES</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team">PEOPLE</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab">INTERLAB</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety">SAFETY</a></li> | |
− | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</a></li> | |
− | + | ||
− | + | ||
− | + | ||
</div> | </div> | ||
− | + | </header> | |
− | + | <br><br><br> | |
+ | <div> | ||
+ | <br><br><br><br> | ||
+ | <video margin-top="5%" width="100%" height="700px" controls autoplay> | ||
+ | <source src="https://static.igem.org/mediawiki/2016/4/41/CGU_Taiwan--video4.mp4" type="video/mp4"> | ||
+ | </video> | ||
</div> | </div> | ||
+ | |||
+ | <br><br><br> | ||
+ | <div class="mid"> | ||
+ | <div style="font-size:60px;color:#140731;text-decoration:none;margin-left:45%;"> | ||
+ | <br><br><br><br> | ||
+ | Abstract | ||
+ | </div> | ||
+ | <br></br> | ||
+ | <br></br> | ||
+ | <b style="color:black;font-size:25px;margin-left:10%;">Leijuvant- A Revolutionary Choice of Vaccine Helper</b><br><br> | ||
+ | <div style="color:black;font-size:18px;margin-left:10%;text-align:justify;"> | ||
+ | For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public. | ||
+ | </div> | ||
+ | <br><br> | ||
+ | </div> | ||
+ | |||
+ | <div class="mid2" style="background-color:#d0d0d0;top:130%;"> | ||
+ | <div style="font-size:60px;color:#140731;margin-left:35%;margin-top:2%;"> | ||
<br> | <br> | ||
+ | Start the Journey | ||
+ | </div> | ||
+ | <br></br> | ||
+ | <br></br> | ||
+ | <a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:10%;" src="https://static.igem.org/mediawiki/2016/4/40/CGU_Taiwan--t4.jpg"> | ||
+ | <h2 style="font-size:35px;color:#140731;position:absolute;left:15%;top:490px;z-index:+1;text-decoration:none;">PROJECT</h2></a> | ||
+ | <a href="http://facebook.com/igemcgu"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:38%;" src="https://static.igem.org/mediawiki/2016/c/cd/CGU_Taiwan--macrophage.jpg"> | ||
+ | <h3 style="font-size:35px;color:#140731;position:absolute;left:45%;top:490px;text-decoration:none;">NEWS</h3></a> | ||
+ | <a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:66%;" src="https://static.igem.org/mediawiki/2016/7/7c/CGU_Taiwan--HA.jpg"> | ||
+ | <h4 style="font-size:35px;color:#140731;position:absolute;left:72%;top:490px;text-decoration:none;">RESULTS</h4></a> | ||
+ | </div> | ||
− | <div | + | <div class="end" style="top:190%;"> |
− | + | <div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;"> | |
− | + | Chang Gung University | |
− | + | ||
</div> | </div> | ||
+ | <br> | ||
+ | <div style="color:white;font-size:15px;margin-left:10%;text-align:justify;"> | ||
+ | No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan (R.O.C.) | ||
+ | <br> | ||
+ | TEL: +886-3-2118800 FAX:+886-3-2118700 | ||
+ | <img src="https://static.igem.org/mediawiki/2016/e/eb/CGU_Taiwan--sponsor0.6.jpg" style="position:absolute;top:0%;margin-left:25%;width:35%;height:45%;margin-top:3%;"> | ||
+ | </div> | ||
+ | </div> | ||
+ | <br><br><br><br><br> | ||
+ | |||
+ | <div class="end2" style="top:210%;"> | ||
+ | <br> | ||
+ | <ul class="list3" class="margin-left:1%;margin-top:2%;"> | ||
+ | <li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li> | ||
+ | </ul> | ||
+ | <br> | ||
+ | <div class="sitemap" style="margin-left:5%;"> | ||
+ | <br> | ||
+ | <b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br> | ||
+ | <br><br> | ||
+ | <img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:50%;height:90%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg"> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:22%;margin-top:-1%;"> | ||
+ | <ul class="list" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:40%;margin-top:-2%;"> | ||
+ | <ul class="list" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a> | ||
+ | <br><br> | ||
+ | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a> | ||
+ | <br><br> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:55%;margin-top:-3.5%;"> | ||
+ | <ul class="list" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a> | ||
+ | <br><br> | ||
+ | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="sitemap" style="margin-left:75%;margin-top:-3.5%;"> | ||
+ | <ul class="list" class="margin-left:5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a> | ||
+ | <br><br> | ||
+ | <ul class="list2" class="margin-left:6%;"> | ||
+ | <li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | <ul class="list" class="margin-left:1%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a> | ||
+ | <br><br> | ||
+ | <ul class="list2" class="margin-left:6%;margin-top:-5%;"> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a> | ||
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a> | ||
+ | </ul> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | </div> | ||
+ | |||
+ | |||
</html> | </html> |
Latest revision as of 07:04, 2 December 2016
![](https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg)
Abstract
Leijuvant- A Revolutionary Choice of Vaccine Helper
For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.
Chang Gung University
No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan (R.O.C.)
TEL: +886-3-2118800 FAX:+886-3-2118700
TEL: +886-3-2118800 FAX:+886-3-2118700
![](https://static.igem.org/mediawiki/2016/e/eb/CGU_Taiwan--sponsor0.6.jpg)